Immune Mechanism And Clinical Effects Of Paclitaxel/Cisplatin Combined With Lentinan In The Treatment Of Advanced Cervical Cancer

Objective: We compare the immune mechanism and clinical effects of paclitaxel/cisplatin combined with lentinan in the treatment of advanced cervical cancer.Methods: We retrospectively analyzed 46 patients with advanced cervical cancer admitted to our hospital from January 2017 to October 2018. They were divided into two groups (23 cases in each group) according to the treatment they had received. The control group was treated with paclitaxel/cisplatin combined with radiotherapy and chemotherapy; the observation group was treated with lentinan for two cycles. The changes in immune cells, short-term efficacy, and adverse reactions were analyzed and compared between the two groups.Results: After treatment, the activity of CD4, CD4/CD8, and NK cells in the observation group was significantly higher than it had been before treatment (P< 0.05). The activity of CD3, CD4, CD4/CD8, and NK cells in the control group was significantly lower than it had been before treatment (P< 0.05). The activity of CD4, CD4/CD8, and NK cells in the observation group was significantly higher than in the control group (P< 0.05). There were no significant differences in the effective rate between the observation group and the control group (P> 0.05). However, the incidence of myelosuppression, nausea, and vomiting was lower in the observation group than in the control group; the difference between the two groups was significant (P< 0.05).Conclusion: Paclitaxel/cisplatin combined with lentinan can significantly improve the immune function of patients with advanced cervical cancer. The clinical effect is positive and the side effects are minor, which improves patients' quality of life. This treatment is worthy of clinical application.